Late Breaking Abstract – ASCO 2026: CEL MoDs Significantly Extend Progression-Free Survival in Relapsed and Refractory Multiple Myeloma
Late Breaking Abstract – ASCO 2026: BREAKWATER Cohort 3 Expands First-Line Targeted Therapy Options for BRAF V600E-Mutant Metastatic Colorectal Cancer
Late Breaking Abstract – ASCO 2026: ctDNA-Guided Early Treatment Escalation Improves Outcomes in EGFR-Mutated Advanced NSCLC
FDA Approves WELIREG® with KEYTRUDA® for Adjuvant Treatment of Renal Cell Carcinoma
FDA Approves IBRANCE® with HER2 Targeted Therapy and Endocrine Therapy as Maintenance Treatment in HR-positive, HER2-positive Advanced Breast Cancer
Late Breaking Abstract – ASCO 2026: Ivonescimab Plus Chemotherapy Delivers Superior Overall Survival Benefit in Advanced Squamous NSCLC
Late Breaking Abstract – ASCO 2026: Evidence for Comprehensive PI3K/AKT/mTOR Pathway Inhibition in HR-Positive, HER2-Negative Advanced Breast Cancer
FDA Approves All-Oral Treatment for Newly Diagnosed Acute Myeloid Leukemia
HERIZON-GEA-01 and the Future of HER2-Targeted Therapy in Gastroesophageal Adenocarcinoma
Late Breaking Abstract – ASCO 2026: Perioperative Apalutamide Plus ADT in High-Risk Localized and Locally Advanced Prostate Cancer
Late Breaking Abstract – ASCO 2026: Adjuvant Selpercatinib Delivers Landmark Event-Free Survival Benefit in Early-Stage RET Fusion–Positive NSCLC
Late Breaking Abstract – ASCO 2026: Daraxonrasib Redefines Second-Line Treatment for Metastatic Pancreatic Cancer
DATROWAY® Demonstrates Survival Advantage in First-Line Metastatic Triple-Negative Breast Cancer
CheckMate-9ER primary and exploratory findings: baseline characteristics and treatment outcomes, including depth and durability of response with cabozantinib plus nivolumab
Late Breaking Abstract – ASCO 2026: Sunvozertinib Demonstrates Superior First-Line Efficacy in EGFR Exon 20 Insertion–Positive Advanced NSCLC
Redefining First-Line Therapy in HER2-Positive Gastroesophageal Adenocarcinoma with Zanidatamab-Based Combinations
ASCO Recommendations for Sentinel Lymph Node Biopsy (SLNB) and Axillary Management in Early-Stage Breast Cancer
Beyond TNM Staging: How ctDNA Is Reshaping Risk Stratification in Stage III Colon Cancer
FDA Approves ENHERTU® for Neoadjuvant Therapy in High-Risk HER2-Positive Early Breast Cancer
FDA Approves ENHERTU® in Postneoadjuvant Care for High-Risk HER2-Positive Early Breast Cancer
Bottom Ad
Advertisement
Subscribe
